Role of Immunohistochemical Markers in Salivary Gland Neoplasms
Keywords:
Salivary Gland Neoplasms, Histomorphology, Haematoxylin-Eosin, Immunohistochemical Markers, P63 and HER2/ neuAbstract
Background: Salivary gland neoplasms are rare. In recent days its incidence is gradually increasing worldwide. Hence, it is essential to diagnose the type and grade these neoplasms for early management. Though histopathological diagnosis is the gold standard for the investigation of various salivary gland neoplasms. Immunohistochemical evaluation plays a vital role in the diagnosis of such neoplasms.
Objective: The present study is done to assess the pattern of expression of various Immunohistochemical markers (IHC) and to evaluate its diagnostic significance over histopathological diagnosis in various salivary gland neoplasms.
Materials and Methods: A total number of 57 cases of salivary gland neoplasm were studied for a period of five years between August 2012 and July 2017. All the biopsy and excised specimen sections were initially examined under routine haematoxylin-eosin stain (H&E). Later immunohistochemical markers were performed, a panel of antibodies such as P63 and HER2/ neu were performed on the sections.
Result: The pattern of expression and significance of each marker, P63 and HER2/ neu, were studied on various salivary gland neoplasms. Reports were compared with the results of conventional histopathology. It was fund that more specific results were obtained in many cases of neoplasm.
Conclusions: We found that P63, which is a nuclear marker is positive in tumours like pleomorphic adenoma, myoepithelioma, mucoepidermoid carcinoma, adenoid cystic carcinoma and carcinoma ex-pleomorphic adenoma. HER2/neu shows diffuse and strong membranous staining in salivary duct carcinoma.
How to cite this article:
Margaret Theresa J, Gerard Rakesh J, Lavanya M. Role of Immunohistochemical Markers in Salivary Gland Neoplasms. Rec Adv Path Lab Med 2019; 5(4): 7-12.
DOI: https://doi.org/10.24321/2454.8642.201920
References
Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology
and genetics of head and neck tumours. Word Health
Organization Classification of Tumours. 2005. Available
from: https://publications.iarc.fr/Book-And-Report-
Series/Who-Iarc-Classification-Of-Tumours/Pathology-
And-Genetics-Of-Head-And-Neck-Tumours-2005.
Rousseau A, Badoual C. Head and neck: Salivary gland
tumors: an overview 2010-09; Atlas id-5328. Available
from: http://atlasgeneticsoncology.org/Tumors/
SalivGlandOverviewID5328.html.
De Oliveira FA, Duarte EC, Taveira CT, Máximo AA, de
Aquino EC, de CássiaAlencar R, Vencio EF. Salivary gland
tumor: a review of 599 cases in a Brazilian population.
Head and neck pathology 2009; 3(4): 271-275. Available
from: https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC2811571/ [PubMed/ Google Scholar].
Barnes L, Eveson JW, Reichart P, Sidransky D. World
Health Organization classification oftumours: pathology
and genetics of head and neck tumours. Word Health
Organization Classification of Tumours: Pathology and
genetics of head and neck tumors. 2005. Available
from: http://apps.who.int/bookorders/anglais/detart1.
jsp?codlan=1&codcol=70&codcch=9.
Tian Z, Li L, Wang L, Hu Y, Li J. Salivary gland neoplasms
in oral and maxillofacial regions: a 23-year retrospective
study of 6982 cases in an eastern Chinese population.
International journal of oral and maxillofacial surgery
; 31; 39(3): 235-242. Available from: https://www.
ijoms.com/article/S0901-5027(09)01139-4/fulltext
[PubMed/ Google Scholar].
Zhu S, Schuerch C, Hunt J. Review and updates of
immunohistochemistry in selected salivary gland
and head and neck tumors. Archives of Pathology
and Laboratory Medicine 2015; 139(1): 55-66.
Available from: https://www.archivesofpathology.org/
doi/ 10.5858/arpa.2014-0167-RA?url_ver=Z39.88-
&rfr_id=ori:rid:crossref.org&rfr_dat=cr_
pub%3dpubmed [PubMed/ Google Scholar].
Prasad AR, Savera AT, Gown AM, Zarbo RJ. The
myoepithelialimmunophenotype in 135 benign and
malignant salivary gland tumors other than pleomorphic
adenoma. Arch Pathol Lab Med 1999; 123(9): 801-806.
Available from: https://www.archivesofpathology.org/
doi/10.1043/0003-9985(1999)123%3C0801:TMIIBA%3
E2.0.CO;2?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.
org&rfr_dat=cr_pub%3dpubmed [PubMed/ Google
Scholar].
Hata M, Amano I, Tsuruga E, Kojima H, Sawa Y.
Immunoelectron microscopic study of podoplanin
localization in mouse salivary gland myoepithelium.
Actahistochemicaetcytochemica 2010; 43(2): 77-
Available from: https://www.semanticscholar.
org/paper/Immunoelectron-Microscopic-Study-of-
Podoplanin-in-Hata-Amano/38ea66deb43fffdc9954
b9e07f5e6f8fd39865e7 [PubMed/ Google Scholar].
Zarbo RJ. Salivary gland neoplasia: a review for the
practicing pathologist. Modern Pathology 2002;
(3): 298. Available from: https://www.nature.com/
articles/3880525 [PubMed/ Google Scholar].
Bilal H, Handra-Luca A, Bertrand JC, Fouret PJ. P63 is
expressed in basal and myoepithelial cells of human
normal and tumor salivary gland tissues. Journal of
Histochemistry & Cytochemistry 2003; 51(2): 133-139.
Available from: https://journals.sagepub.com/doi/fu
ll/10.1177/002215540305100201?url_ver=Z39.88-
&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_
pub%3Dpubmed [PubMed/ Google Scholar].
Raboh NM, Hakim SA. Diagnostic role of DOG1 and p63
immunohistochemistry in salivary gland carcinomas.
International journal of clinical and experimental
pathology 2015; 8(8): 9214. Available from: https://
www.semanticscholar.org/paper/Diagnostic-role-of-
DOG1-and-p63-in-salivary-gland-Raboh-Hakim/472
a3cf95f3f20f1ce77f7490d5c5ecf1a2facf [PubMed/
Google Scholar].
Edwards PC, Bhuiya T, Kelsch RD. C-kit expression in
the salivary gland neoplasms adenoid cystic carcinoma,
polymorphous low-grade adenocarcinoma and
monomorphic adenoma. Oral Surgery, Oral Medicine,
Oral Pathology, Oral Radiology, and Endodontology
; 95(5): 586-593. Available from: https://www.
oooojournal.net/article/S1079-2104(02)91632-X/
fulltext [PubMed/ Google Scholar].
Omitola OG, Iyogun CA. Immunohistochemical study
of salivary gland tumors in a tertiary institution in
South-South Region of Nigeria. Journal of oral and
maxillofacial pathology: JOMFP 2018; 22(2): 163-
Available from: http://www.jomfp.in/article.
asp?issn=0973-029X;year=2018;volume=22;issue=
;spage=163;epage=167;aulast=Omitola [PubMed/
Google Scholar].
Genelhu MC, Gobbi H, Soares FA, de Marques
AH, Ribeiro CA, Cassali GD. Immunohistochemicalexpression of p63 in pleomorphic adenomas and
carcinomas ex-pleomorphic adenomas of salivary
glands. Oral oncology 2006; 42(2): 154-160. Available
from: https://www.sciencedirect.com/science/article/
abs/pii/S1368837505002022 [PubMed/ Google
Scholar/ ResearchGate].
Singh AD, Majumdar S, Ghosh AK,Gandi L, Choudaha N,
Sharma I, Pal SP. Basal Cell AdenomaClinicopathological,
Immunohistochemical Analysis and Surgical
Considerations of a Rare Salivary Gland Tumor with
Review of Literature. Nigerian Journal of Surgery 2015;
(1): 31-34. Available from: http://www.nigerianjsurg.
com/article.asp?issn=1117-6806;year=2015;volum
e=21;issue=1;spage=31;epage=34;aulast=Bhagat
[PubMed/ Google Scholar].
Alotaibi AM, Alqarni MA, Alnobi A, Tarakji B. Human
epidermal growth factor receptor (HER2/neu) in
salivary gland carcinomas: a review of literature. Journal
of Clinical and Diagnostic Research: JCDR 2015; 9(2):
ZE04. [PubMed/ Google Scholar].
Nagao T, Sato E, Inoue R, Oshiro H, Takahashi RH, Nagai
T et sl. Immunohistochemical analysis of salivary gland
tumors: application for surgical pathology practice.
Actahistochemicaetcytochemica 2012; 45(5): 269-282.
[PubMed/ Google Scholar].
Downloads
Published
Issue
Section
License
We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
Important
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.
